Authors



Autumn Vaupel

Latest:

Sustaining Pace With Contingent Workers

Pandemic workforce trends continue to create challenges for pharma.



The Whyse

Latest:

Word to the Whyse presents: The Science of Engagement

*** Time and Date: Tuesday, November 17 I 11:00 am – 2:30 pm EST *** *** On-demand available after final airing until Nov. 17, 2021***


Michael Lynch

Latest:

Overcoming HCP Engagement Fatigue with Data-Driven Insights

With a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.


Julia Libunao

Latest:

Why Program Management is the Key to Success for Life Science Companies

Delivering value with enterprise program management.


Phreesia

Latest:

Trends to Watch in Patient-first Pharma Marketing

As healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.


Leanne Larson

Latest:

Industry Game Changer: RWE Impacts on Drug Development

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.


Smita Pillai

Latest:

The Harms of ‘Helicopter Research’ in the Life Sciences

How pharma companies can make justice and integrity a priority.



Michael Howley PA-C, MBA, PhD

Latest:

Data Intermediaries/Software Can Speed the Usage of Real-World Data

Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.


Sarah Averill Lott

Latest:

Open Science and Digital Health: A Brighter Future for Parkinson’s Disease

Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.



Shiying He

Latest:

China’s 2022 NRDL Readout

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.


Scott Snyder

Latest:

Pharmatizing AI

Using the 3 Rs to guide AI transformation in Pharma.


Noam Solomon

Latest:

Leverage AI to Lower Cost, Barriers to Cell Therapies

Off-the-shelf cell therapies hold immense promise for revolutionizing precision medicine by offering accessible and affordable treatments. However, overcoming the immune system's rejection and navigating the FDA's approval process are crucial challenges.


Doron Aspitz

Latest:

Harnessing AI for Pharma Sales

Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.


Janardan Prasad

Latest:

How A Self-Service Data Platform for Life Sciences Analytics Can Fast-Track Drug Readiness

Owning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.


Dave Hanaman

Latest:

A Crossroads for the Digital Therapeutics Industry. Now is the Time to Act

Recent events can provide digital therapeutics companies with clear lessons for the future.


Michelle Marlborough

Latest:

Why Machine Learning's Potential in Pharma Relies on Its Transparency

Despite the rapid innovation of machine learning, correct protocols to ensure compliance and trustworthiness must be considered.


Joe Nipko

Latest:

Overcoming AI Bias Within Life Sciences

How to cultivate trust & connections in life sciences in a time of AI bias.


Veronica Sandoval, PhD

Latest:

Harnessing the Power of Communities to Combat Healthcare Inequities

Biopharma has a responsibility to meet patients where they are.


Dennis Fournogerakis

Latest:

To Reduce Commercial Risk for Orphan Drugs, Transform Forecasting

To successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.


Helen Merianos

Latest:

The Leap Forward: Practical Gains for Pharma AI Use

Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.


Amy Morgan

Latest:

The Emergence of Commercial Health Insurances as an Access Route to the Chinese Market

Commercial Health Insurance may bring more opportunities for market access in China.


Chiraag Bhadana

Latest:

AI’s Promise in Delivering on Patient-Centricity

How pharmaceutical companies can utilize AI at key stages of the treatment journey to enhance patient-centric engagement by increasing empathy and humanity in patient interactions.


Sarah Murchison

Latest:

Startup Launch Guide: Avoiding 10 Common Pain Points

With opportunity and risk lurking in equal measure, today’s key considerations for biopharma startups when building their leadership teams and product go-to-market strategies are outlined.



Christian Hinneburg

Latest:

Strategic Decision-Making in Early-Stage Drug Development and Lifecycle Management to Maximize a Drug’s Lifetime Value

Presenting a structured, decision-making approach for executive management to make sound strategic decisions for drug development and life cycle management.


Sadik Kassim

Latest:

Three Key Steps to Unlocking mRNA’s Potential Beyond COVID-19

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.